Brief: Kronos Bio Reports Recent Business Progress And First-Quarter 2023 Financial Results
10/05/2023 21:17
May 10 (Reuters) - Kronos Bio Inc KRON.O :
* KRONOS BIO REPORTS RECENT BUSINESS PROGRESS AND
FIRST-QUARTER
2023 FINANCIAL RESULTS
* $241.3 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS
AS OF
MARCH 31, 2023, PROVIDING EXPECTED CASH RUNWAY INTO 2H 2025
* KATHERINE VEGA STULTZ AND ROGER DANSEY, M.D., APPOINTED TO
BOARD
OF DIRECTORS
* ENROLLMENT ONGOING IN EXPANSION PORTION OF PHASE 1/2
KB-0742
STUDY, WITH INITIAL EFFICACY DATA EXPECTED IN 2H 2023
* QTRLY LOSS PER SHARE $0.46
* Q1 EARNINGS PER SHARE VIEW $-0.45 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX9xdnDz
Further company coverage: KRON.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kronos Bio
See all newsBrief: Kronos Bio Inc - Terminates Office Lease At 301 Binney Street - SEC Filing
Brief: Kronos Bio Inc - Enters Transition Agreement With Genentech
U.S. STOCKS ON THE MOVE - Ambarella, Dell, Nordstrom
U.S. STOCKS ON THE MOVE - Golden Ocean, Guess, Symbotic
U.S. STOCKS ON THE MOVE-HP, Urban Outfitters, 3D Systems